Erythrocyte-binding therapeutics

Patent metadata

Field	Value
Publication number	US-9850296-B2
Application number	US-201414460768-A
Country	US
Kind code	B2
Filing date	Aug 15, 2014
Priority date	Aug 10, 2010
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

First claim

The invention claimed is:

1. A pharmaceutically acceptable composition comprising an erythrocyte-binding moiety, a linker, and a tolerogenic antigen , which are recombinantly fused or chemically conjugated, wherein:
said erythrocyte-binding moiety is an antibody fragment having the ability to noncovalently and specifically bind to glycophorin A on a human erythrocyte in situ in blood,
said linker is a peptide, a covalent bond a nucleic acid or a particle; and
said tolerogenic antigen is a self antigen to which patients develop an unwanted immune response, wherein the self antigen comprises insulin, proinsulin, preproinsulin, or an antigenic fragment of insulin, proinsulin or preproinsulin.

2. The pharmaceutically acceptable composition of claim 1 wherein said linker is a covalent bond.

3. The pharmaceutically acceptable composition of claim 1 wherein administration of said composition results in reductions in diabetogenic T cells in a spleen or liver of a subject receiving the composition.

4. The pharmaceutically acceptable composition of claim 1 characterized by having the ability to induce apoptotic- or exhausted-fate proliferation and/or deletion of CD4+ and/or CD8+ T-cells specific for the antigen, or the ability to induce regulatory cell phenotypes.

5. The pharmaceutically acceptable composition of claim 1 wherein the tolerogenic antigen is proinsulin or an antigenic fragment thereof.

6. The pharmaceutically acceptable composition of claim 1 wherein the tolerogenic antigen comprises a mimotope of a protein.

7. The pharmaceutically acceptable composition of claim 1 wherein said linker is a branched polymer that increases the affinity of erythrocyte binding by avidity effects.

8. The pharmaceutically acceptable composition of claim 7 wherein said branched polymer is conjugated to more than one erythrocyte-binding moiety.

9. A method of treating an unwanted immune response comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutically acceptable composition, the composition comprising an erythrocyte-binding moiety, a linker, and a tolerogenic antigen , which are recombinantly fused or chemically conjugated, wherein:
said erythrocyte-binding moiety is an antibody fragment having the ability to noncovalently specifically bind to glycophorin A on a human erythrocyte in situ in blood,
said linker is a peptide, a covalent bond, a nucleic acid or a particle;
said tolerogenic antigen is a self antigen to which patients develop an unwanted immune response, wherein the self antigen comprises insulin, proinsulin, preproinsulin, or an antigenic fragment of insulin, proinsulin or preproinsulin.

10. The method of claim 9 characterized by having the ability to induce apoptotic- or exhausted-fate proliferation and/or deletion of CD4+ and/or CD8+ T-cells specific for the antigen, or the ability to induce regulatory cell phenotypes.

11. The method of claim 9 wherein said composition is administered to a patient prior to an unwanted immune response to the antigen, wherein said treatment prevents or minimizes the unwanted immune response.

12. The method of claim 9 wherein said composition is administered to a patient having an unwanted immune response to the antigen, wherein said treatment reverses or minimizes the unwanted immune response.

13. The method of claim 9 where the unwanted immune response is type 1 diabetes mellitus.

14. The method of claim 9 wherein the tolerogenic antigen is proinsulin or an antigenic fragment thereof.

15. A pharmaceutically acceptable composition comprising an erythrocyte-binding moiety, and a tolerogenic antigen, which are recombinantly fused or chemically conjugated, wherein:
said erythrocyte-binding moiety is an antibody fragment binding to human glycophorin A; and
said tolerogenic antigen is a self antigen which induces an unwanted immune response, wherein the self antigen comprises insulin, proinsulin, preproinsulin, glutamic acid decarboxylase-65 (GAD65), GAD-67, islet-specific glucose-6-phosphatase catalytic subunit-related protein or fragments thereof.

16. A pharmaceutically acceptable composition comprising:
an erythrocyte-binding moiety;
said erythrocyte-binding moiety is an antibody directed to human glycophorin A thereby allowing the composition to specifically bind erythrocytes; and

a tolerogenic antigen,
wherein said tolerogenic antigen is a self-antigen to which a subject develops an unwanted immune response,
wherein the self-antigen is associated with type 1 diabetes, and

wherein the erythrocyte-binding moiety and the tolerogenic antigen are chemically conjugated to one another.

17. A pharmaceutically acceptable composition, comprising:
an erythrocyte-binding moiety,
said erythrocyte-binding moiety is an antibody fragment having the ability to noncovalently and specifically bind to glycophorin A on a human erythrocyte in situ in blood;

a tolerogenic antigen,
wherein said tolerogenic antigen is a self-antigen to which a subject develops an unwanted immune response,
wherein the self-antigen is associated with type 1 diabetes,
wherein the self-antigen is an islet antigen recognized by diabetogenic T cells, wherein the erythrocyte-binding moiety and tolerogenic antigen are recombinantly fused or chemically conjugated.

18. The pharmaceutically acceptable composition of claim 17 , wherein the islet antigen recognized by diabetogenic T cells is selected from the group consisting of chromogranin A, insulin, proinsulin, preproinsulin, an antigenic fragment thereof, or a mimotope thereof.

19. The pharmaceutically acceptable composition of claim 17 , wherein the erythrocyte-binding moiety and tolerogenic antigen are recombinantly fused.

20. The pharmaceutically acceptable composition of claim 17 , wherein the tolerogenic antigen comprises an immunogenic mimotope of chromogranin A.

21. The pharmaceutically acceptable composition of claim 20 , wherein the immunogenic mimotope of chromogranin A comprises the sequence of SEQ ID NO:77.

Assignees

• Ecole Polytechnique Fed De Lausanne (Epfl)

Inventors

• Hubbell Jeffrey A
• Kontos Stéphane
• Dane Karen Y

Classifications

• A61K47/48246

  Human Necessities · mapped topic

• C07K2319/21

  containing a His-tag · CPC title

• C12N9/82

  Asparaginase {(3.5.1.1)} · CPC title

• A61K39/0008

  Antigens related to auto-immune diseases; Preparations to induce self-tolerance · CPC title

• A61K2039/6056

  Antibodies · CPC title